Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer patients get continued access to atezolizumab in Long-Term study

NCT ID NCT03148418

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study offers continued treatment with atezolizumab (Tecentriq) for cancer patients who were already receiving it in a prior Roche-sponsored trial. It includes 382 participants and aims to provide uninterrupted therapy while monitoring long-term safety and survival. The study is not testing a new approach but ensuring patients maintain access to their current treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Atezolizumab (Tecentriq) with or without bevacizumab (Avastin)
What this could lead to
If successful, this study ensures patients can continue their cancer treatment without interruption and provides long-term safety data.
What could go wrong
This is an extension study, not a new treatment test. It does not prove the drug works better than alternatives, and side effects remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

382 people

The number who actually took part.

Started

Sep 2017

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Specific criteria for patients who continue treatment as well as safety and survival follow-up in the extension study (and survival follow up for pattients who roll over from IMpower133): * Eligible for continuing or crossing over to atezolizumab-based therapy at the time of the parent-study closure as per the parent study or eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study at the time of the parent-study closure as per the parent study, with no access to commercially available comparator agent * First dose of study treatment in the extension study will be received within 7 days of the treatment interruption window allowed by the parent study * Continue to benefit from atezolizumab-based study treatment or from the comparator at the time of parent-study closure as assessed by the investigator * Negative serum pregnancy test within 7 days prior to start of study treatment in women of childbearing potential Specific criteria for patients from the IMpower133 parent study only who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study: \- Discontinuation of atezolizumab-based therapy in the IMpower133 parent study and in survival follow- up at the time of IMpower133 parent study closure, or eligible for continuing or crossing over to atezolizumab-based therapy as per the IMpower133 parent protocol and have access to commercially available atezolizumab (Tecentriq) outside this extension study at the time of the IMpower133 parent-study closure Exclusion Criteria: Specific criteria for patients who continue treatment as well as safety and survival follow-up in the extension study: * Meet of any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in the extension study * Study treatment is commercially marketed in the patient's country for the patient specific disease and is accessible to the patient * Time between the last dose of treatment received in parent study and first dose in extension study is longer than the interruption period (± 7 days) allowed in the parent study * Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in the extension study * Permanent discontinuation of atezolizumab for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study (if applicable) * Any unresolved or irreversible toxicities during the parent study that required permanent discontinuation of study treatment, in accordance to the parent study or local prescribing information * Ongoing SAE(s) that has not resolved to baseline level or Grade less than or equal to (\<=) 1 from the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study * Any serious uncontrolled concomitant disease that would contraindicate the use of study treatment at the time of the extension study or that would place the participant at high risk for treatment-related complications * Concurrent participation in any therapeutic clinical trial (other than the parent study) Specific criteria for patients who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study: \- Discontinuation of comparator in parent study and in survival follow-up at the time of parent study closure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • A.O. Universitaria Pisana-Ospedale Cisanello

    Pisa, Tuscany, 56124, Italy

  • A.O. Universitaria Policlinico Di Modena

    Modena, Emilia-Romagna, 41100, Italy

  • A.O.U. Maggiore della Carità

    Novara, Piedmont, 28100, Italy

  • ASL 3 Genovese

    Genoa, Liguria, 16149, Italy

  • AZ Glorieux- vzw Werken Glorieux

    Ronse, 9600, Belgium

  • Allegheny Cancer Center

    Pittsburgh, Pennsylvania, 15212, United States

  • Angeles Clinic & Rsch Inst

    Los Angeles, California, 90025, United States

  • Asst Di Monza

    Monza, Lombardy, 20900, Italy

  • Auckland city hospital

    Auckland, 1023, New Zealand

  • Azienda Osp Uni Seconda Università Degli Studi Di Napoli

    Naples, Campania, 80131, Italy

  • Azienda Ospedaliera A. Cardarelli

    Naples, Campania, 80131, Italy

  • Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica

    Siena, Tuscany, 53100, Italy

  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga

    Orbassano, Piedmont, 10043, Italy

  • Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato

    Arezzo, Tuscany, 52100, Italy

  • Barts & London School of Med

    London, EC1A 7BE, United Kingdom

  • Belinson Medical Center

    Petah Tikva, 4922297, Israel

  • Beth Israel Medical Center

    Boston, Massachusetts, 02215, United States

  • Blue Ridge Cancer Care

    Roanoke, Virginia, 24014, United States

  • Bradford Hill Centro de Investigaciones Clinicas

    Recoleta, 8420383, Chile

  • CH de Saint Quentin

    Saint-Quentin, 2100, France

  • CHU de Toulouse - Hôpital Larrey

    Toulouse, 31059, France

  • CHUV

    Lausanne, 1011, Switzerland

  • Carolina BioOncology Institute, PLCC

    Huntersville, North Carolina, 28078, United States

  • Centre Antoine Lacassagne, Centre de Lutte Contre le Cancer (CLCC) de Nice

    Nice, 06189, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495, France

  • Centre Leon Berard

    Lyon, 69373, France

  • Centre Medico-Chirurgical Foch

    Suresnes, 92151, France

  • Centre René Gauducheau - cancer Nantes - Atlantique

    Nantes, 44805, France

  • Centro Hospitalar do Porto ? Hospital de Santo António

    Porto, 4099-001, Portugal

  • Changhua Christian Hospital

    Changhua, 500, Taiwan

  • Charing Cross Hospital

    London, W6 8RF, United Kingdom

  • China Medical University Hospital

    Taichung, 40447, Taiwan

  • Chonnam National University Hwasun Hospital

    Jeollanam-do, 58128, South Korea

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, 2050, Australia

  • Christie Hospital NHS Trust

    Manchester, M20 4BX, United Kingdom

  • Chu Grenoble - Hopital Albert Michallon

    Grenoble, 38043, France

  • Chulalongkorn Hospital

    Bangkok, 10330, Thailand

  • Cite de La Sante de Laval

    Laval, Quebec, H7M 3L9, Canada

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Clinic for Pulmonology, Clinical Center of Serbia

    Belgrade, 11000, Serbia

  • Clinica Universitaria de Navarra

    Pamplona, Navarre, 31008, Spain

  • Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología

    A Coruña, LA Coruna, 15006, Spain

  • Complejo Hospitalario de Jaen

    Jaén, 23007, Spain

  • Comprehensive Cancer Centers of Nevada - Eastern Avenue

    Las Vegas, Nevada, 89169, United States

  • Dana Farber Cancer Inst.

    Boston, Massachusetts, 02215, United States

  • Faculty of Med. Siriraj Hosp.

    Bangkok, 10700, Thailand

  • Florida Cancer Specialists - Fort Myers (Broadway)

    Fort Myers, Florida, 33901, United States

  • Florida Cancer Specialists.

    St. Petersburg, Florida, 33705, United States

  • Fundacao Antonio Prudente

    São Paulo, São Paulo, 01509-900, Brazil

  • Fundación CENIT para la Investigación en Neurociencias

    Buenos Aires, C1125ABD, Argentina

  • GH Paris Saint Joseph

    Paris, 75674, France

  • Georgetown University Medical Center Lombardi Cancer Center

    Washington D.C., District of Columbia, 20057, United States

  • H. Lee Moffitt Cancer Center and Research Inst.

    Tampa, Florida, 33612, United States

  • Hacettepe Uni Medical Faculty Hospital

    S?hhiye, Ankara, 06100, Turkey (Türkiye)

  • Hematology Oncology Associates of the Treasure Coast

    Port Saint Lucie, Florida, 34952, United States

  • HonorHealth Research Institute ? Bisgrove

    Scottsdale, Arizona, 85258, United States

  • Hopital Jean Minjoz

    Besançon, 25030, France

  • Hopital Nord

    Marseille, 13915, France

  • Hopital Saint Louis

    Paris, 75475, France

  • Hopital Tenon

    Paris, 75970, France

  • Hospital Clinic de Barcelona. Unidad de Nuevas Terapias

    Barcelona, 08036, Spain

  • Hospital General Universitario Gregorio Marañon

    Madrid, 28007, Spain

  • Hospital General Universitario de Valencia

    Valencia, 46014, Spain

  • Hospital Lucus Augusti

    Lugo, 27003, Spain

  • Hospital NisA 9 de Octubre

    Valencia, 46015, Spain

  • Hospital Ramon y Cajal

    Madrid, 28034, Spain

  • Hospital Regional Universitario Carlos Haya

    Málaga, 29010, Spain

  • Hospital San Pedro De Alcantara

    Cáceres, 10003, Spain

  • Hospital Son Llatzer

    Palma de Mallorca, Balearic Islands, 07198, Spain

  • Hospital Universitari Germans Trias i Pujol

    Barcelona, 08916, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Clínico San Carlos

    Madrid, 28040, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario Materno Infantil de Gran Canaria

    Las Palmas de Gran Canaria, LAS Palmas, 35016, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Cordoba, 14004, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, 41013, Spain

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, 14784-400, Brazil

  • Hospital de Madrid Norte Sanchinarro- Centro Integral Oncologico Clara Campal

    Madrid, 28050, Spain

  • Hospital de Santa Maria

    Lisbon, 1649-035, Portugal

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08041, Spain

  • Hospital del Mar

    Barcelona, 08003, Spain

  • IOV - Istituto Oncologico Veneto - IRCCS

    Padova, Veneto, 35128, Italy

  • IRCCS AOU San Martino - IST

    Genoa, Liguria, 16132, Italy

  • Illinois Cancer Care

    Peoria, Illinois, 61615, United States

  • Ingalls Memorial Hospital

    Harvey, Illinois, 60426, United States

  • Institut Catala d Oncologia Hospital Duran i Reynals

    Barcelona, 08908, Spain

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut Oncologic Ion Chiricuta

    Cluj-Napoca, 400015, Romania

  • Institute of Oncology Ljubljana

    Ljubljana, 1000, Slovenia

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, 01246-000, Brazil

  • Irccs Istituto Europeo Di Oncologia (IEO)

    Milan, Lombardy, 20141, Italy

  • Irccs Istituto Nazionale Dei Tumori (Int)

    Milan, Lombardy, 20133, Italy

  • Istanbul Uni Cerrahpasa Medical Faculty Hospital

    Istanbul, 34300, Turkey (Türkiye)

  • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale

    Naples, Campania, 80131, Italy

  • Iwate Medical University Hospital

    Numakunai, 028-3695, Japan

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

  • Johns Hopkins Univ Med Center

    Baltimore, Maryland, 21231, United States

  • Kaiser Permanente - San Diego (Zion Ave)

    San Marcos, California, 92078, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Klinik Penzing

    Vienna, 1140, Austria

  • Klinikum d.Universität München Campus Großhadern

    München, 81377, Germany

  • Krankenhaus Nord - Klinik Floridsdorf

    Vienna, 1210, Austria

  • Lakeridge Health Corporation-Oshawa

    Oshawa, Ontario, L1G 2B9, Canada

  • Maryland Oncology Hematology, P.A.

    Columbia, Maryland, 21044, United States

  • Masarykuv onkologicky ustav

    Brno, 656 53, Czechia

  • Massachusetts General Hospital.

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan-Kettering Cancer Center

    New York, New York, 10065, United States

  • Moscow City Oncology Hospital #62

    Moscovskaya Oblast, Moscow Oblast, 143423, Russia

  • Multiprofile Hospital for Active Treatment Serdika EOOD

    Sofia, 1303, Bulgaria

  • Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU

    Dnipropetrovsk, 49102, Ukraine

  • NKI/AvL

    Amsterdam, 1066 CX, Netherlands

  • Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad

    Warsaw, 02-781, Poland

  • National Cancer Center

    Gyeonggi-do, 10408, South Korea

  • National Taiwan Uni Hospital

    Taipei, 100, Taiwan

  • New England Cancer Specialists

    Westbrook, Maine, 04092, United States

  • New York Oncology Hematology, P.C.

    Albany, New York, 12206, United States

  • Niigata Cancer Center Hospital

    Niigata, 951-8566, Japan

  • Northwest Cancer Specialists - Portland (N Broadway)

    Portland, Oregon, 97227, United States

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital

    Marietta, Georgia, 30060, United States

  • Northwest Medical Specialties

    Tacoma, Washington, 98405, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Nottingham City Hospital

    Nottingham, NG5 1PB, United Kingdom

  • ONCOMED - Medical Centre

    Timișoara, 300239, Romania

  • Oddzia? Onkologii Klinicznej i Chemioterapii Szpitala ELBL?SKA

    Warsaw, 01-748, Poland

  • Okayama University Hospital

    Okayama, 700-8558, Japan

  • Oncology Associates of Oregon, P.C

    Eugene, Oregon, 97401, United States

  • Ospedale Santa Maria Della

    Perugia, Umbria, 06129, Italy

  • Penn State Hershey Cancer Institute

    Hershey, Pennsylvania, 17033, United States

  • Policlinico Vittorio Emanuele

    Catania, Sicily, 95123, Italy

  • Princess AleXandra Hospital

    Woolloongabba, Queensland, 4102, Australia

  • Princess Margaret Cancer Center

    Toronto, Ontario, M5G 1Z5, Canada

  • Ramathibodi Hospital

    Bangkok, 10400, Thailand

  • Református Pulmonológiai Centrum

    Törökbálint, 2045, Hungary

  • Rocky Mountain Cancer Ctr - Denver (Williams)

    Denver, Colorado, 80218, United States

  • Royal Free Hospital

    London, NW3 2QG, United Kingdom

  • Royal Marsden Hospital - London

    London, SW3 6JJ, United Kingdom

  • Royal Marsden Hospital - Surrey

    Surrey, SM2 5PT, United Kingdom

  • Royal Victoria Hospital

    Barrie, Ontario, L4M 6M2, Canada

  • Rush University Medical Center

    Chicago, Illinois, 60612-3244, United States

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Sarah Cannon Res Inst

    Nashville, Tennessee, 37203, United States

  • Semmelweis Egyetem X

    Budapest, 1083, Hungary

  • Sendai Kousei Hospital

    Miyagi, 981-0914, Japan

  • Seoul National University Bundang Hospital

    Gyeonggi-do, 13620, South Korea

  • Shikoku Cancer Center

    Ehime, 791-0280, Japan

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut, 06510, United States

  • St George's Hospital

    London, SW17 0QT, United Kingdom

  • Summit Medical Center

    Florham Park, New Jersey, 07932, United States

  • Sunnybrook Odette Cancer Centre

    Toronto, Ontario, M4N 3M5, Canada

  • Texas Oncology - DFW

    Dallas, Texas, 75246, United States

  • The Cancer Institute Hospital of JFCR, Respiratory Medicine

    Tokyo, 135-8550, Japan

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    Metropolitan Borough of Wirral, L63 4JY, United Kingdom

  • Thomayerova nemocnice

    Praha 4 - Krc, 140 59, Czechia

  • Toranomon Hospital

    Tokyo, 105-8470, Japan

  • Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi

    Edirne, 22030, Turkey (Türkiye)

  • Tyler Cancer Center

    Tyler, Texas, 75702, United States

  • UCLA

    Los Angeles, California, 90095, United States

  • US oncology research at Minnesota Oncology

    Saint Louis Park, Minnesota, 55416, United States

  • University Hospital Medical Center Bezanijska kosa

    Belgrade, 11080, Serbia

  • University Of Chicago Medical Center

    Chicago, Illinois, 60637, United States

  • University Of Colorado

    Aurora, Colorado, 80045, United States

  • University of Washington Seattle Cancer Care Alliance

    Seattle, Washington, 98109, United States

  • Università Cattolica Del S Cuore

    Rome, Lazio, 00168, Italy

  • Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii

    Gdansk, 80-952, Poland

  • Vall d'Hebron Institute of Oncology (VHIO), Barcelona

    Barcelona, 08035, Spain

  • Virginia Oncology Associates

    Norfolk, Virginia, 23502, United States

  • Wakayama Medical University Hospital

    Wakayama, 641-8510, Japan

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • William Osler Health Centre

    Brampton, Ontario, L6R 3J7, Canada

  • ZAS Sint Augustinus Wilrijk

    Wilrijk, 2610, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.